Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

 Blogroll
ARM Achieves 10 Billion Processor Milestone

ARM Achieves 10 Billion Processor Milestone

Jan 22 2008 | comment(s)

CAMBRIDGE, England, January 22 /PRNewswire/ --

- More Than One Processor for Every Person in the World

- Annual Run Rate Now Three Billion Processor Shipments Across Very Diverse Markets

ARM (LSE:ARM); (Nasdaq: ARMHY) today announced that the total number of processors shipped by its Partners has exceeded ten billion. The company developed its first embeddable RISC core, the ARM6(tm) processor, in 1991, and its semiconductor Partners currently ship almost three billion ARM Powered(R) processors each year.

HSBC Joins IdenTrust's Global Network To Provide High Assurance Identity Solutions To Select Customers

HSBC Joins IdenTrust's Global Network To Provide High Assurance Identity Solutions To Select Customers

Jan 22 2008 | comment(s)

SAN FRANCISCO, January 22 /PRNewswire/ --

- Announcement Underscores HSBC's Commitment to Safeguarding Online Customer Transactions, Delivering Highest Level of Trust for Online Commerce

Progentix Orthobiology B.V. Closes Series A Financing Round

Progentix Orthobiology B.V. Closes Series A Financing Round

Jan 22 2008 | comment(s)

BILTHOVEN, The Netherlands, January 22 /PRNewswire/ -- Progentix Orthobiology B.V. announced today the closure of its Series A financing Round. The round was led by BioGeneration Ventures.

Classic Menu For Office 2007 V.3.90 -- Bringing The Comfort Of MS Office 2003 Interface To MS Office 2007

Classic Menu For Office 2007 V.3.90 -- Bringing The Comfort Of MS Office 2003 Interface To MS Office 2007

Jan 22 2008 | comment(s)

HAIKOU, China, January 22 /PRNewswire/ --

Addintools is delighted to announce the immediate availability of the newest bug-free version of its award-winning Classic Menu for Office 2007. The software has been relieved of occasional lags and runs perfectly on every computer.

Microsoft Announces New E-Government Platform To Put Technology To Work For Governments And Citizens

Microsoft Announces New E-Government Platform To Put Technology To Work For Governments And Citizens

Jan 22 2008 | comment(s)

BERLIN, January 22 /PRNewswire/ --

- Citizen Service Platform will enable greater responsiveness to citizens' needs, efficient delivery of services and cost-effective offerings via the internet.

Microsoft Corp today announced a new strategy that will make it easier for governments to interact with citizens, streamline processes and, as a result, save time and taxpayer money. At the Government Leaders Forum-Europe in Berlin, Microsoft unveiled the Citizen Service Platform (CSP), an approach to help governments of all sizes more responsively deliver services to citizens via the internet.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO )

Synosia Announces Encouraging Results Of Proof-of-Concept Clinical Trial For Epilepsy Drug Rufinamide As A Treatment For Mood Di

Synosia Announces Encouraging Results Of Proof-of-Concept Clinical Trial For Epilepsy Drug Rufinamide As A Treatment For Mood Di

Jan 22 2008 | comment(s)

SAN FRANCISCO, January 22 /PRNewswire/ --

- Speed in Reaching First Clinical Milestone Validates Approach

Synosia Therapeutics today announced the successful completion of its first clinical trial, a proof-of-concept study that evaluated new therapeutic options for SYN-111 (rufinamide), a sodium channel blocker. Rufinamide was discovered and developed by Novartis and is currently marketed by Eisai in Europe as a drug to treat a form of epilepsy. This first trial was completed in less than seven months from design to final dosing and less than a year after the rights to rufinamide in mood disorders were obtained from Novartis in an exclusive licensing agreement.